Neutrophil percentage-to-albumin ratio: is it useful in oropharyngeal cancer?

Mónica Teixeira; Rita V. Osório; Joana F. Rebelo; Leandro Ribeiro; Sandra Alves; Pedro Oliveira

doi:10.18203/issn.2454-5929.ijohns20253801

Authors

Mónica Teixeira Department of Otolaryngology, Unidade Local de Saúde Gaia/Espinho, Portugal
Rita V. Osório Department of Otolaryngology, Unidade Local de Saúde Gaia/Espinho, Portugal
Joana F. Rebelo Department of Otolaryngology, Unidade Local de Saúde Gaia/Espinho, Portugal
Leandro Ribeiro Department of Otolaryngology, Unidade Local de Saúde Gaia/Espinho, Portugal
Sandra Alves Department of Otolaryngology, Unidade Local de Saúde Gaia/Espinho, Portugal
Pedro Oliveira Department of Otolaryngology, Unidade Local de Saúde Gaia/Espinho, Portugal

DOI:

https://doi.org/10.18203/issn.2454-5929.ijohns20253801

Keywords:

Oropharyngeal cancer, Biomarker, Disease-free survival, Recurrence, Survival analysis

Abstract

Background: Host determinants, including nutritional status and systemic inflammation, are critical in the body's response to cancer. Neutrophil percentage-to-albumin ratio (NPAR) has emerged as a promising prognostic marker, however, its significance in head and neck cancer has yet to be fully established. This study aims to evaluate pretreatment NPAR as a predictor of disease-free survival, overall survival and cancer-specific survival in patients with oropharyngeal carcinoma.

Methods: This retrospective cohort study included 88 patients diagnosed with oropharyngeal squamous cell carcinoma (OPSCC) who underwent curative-intent treatment between January 1, 2010, and January 1, 2023. NPAR levels were assessed between diagnosis and treatment initiation. ROC analysis identified the optimal NPAR cutoff value of 16.09, which was used to categorize patients into low-NPAR and high-NPAR groups.

Results: High NPAR (≥16.09) was significantly associated with tumor persistence or recurrence (OR=5.70; p<0.001). Disease-free survival, 5-year overall survival and 5-year cancer-specific survival were all significantly shorter among patients with NPAR ≥16.09. In fact, high-level NPAR group had over than 3-fold increased risk of cancer-specific death at 5 years (HR=3.440; p=0.006).

Conclusions: Our findings indicate that a NPAR ≥16.09 may be associated with poorer outcomes in oropharyngeal cancer. While NPAR shows potential as a prognostic biomarker to complement the TNM staging system, further validation in larger, prospective studies is warranted.

Metrics

Metrics Loading ...

References

Ferlay J, Colombet M, Soerjomataram I, Parkin DM, Piñeros M, Znaor A, et al. Cancer statistics for the year 2020: An overview. Int J Cancer. 2021. DOI: https://doi.org/10.1002/ijc.33588

Lim YX, D'Silva NJ. HPV-associated oropharyngeal cancer: in search of surrogate biomarkers for early lesions. Oncogene. 2024;43(8):543-54. DOI: https://doi.org/10.1038/s41388-023-02927-9

Zumsteg ZS, Luu M, Rosenberg PS, Elrod JK, Bray F, Vaccarella S, et al. Global epidemiologic patterns of oropharyngeal cancer incidence trends. Journal of the National Cancer Institute. 2023;115(12):1544-54. DOI: https://doi.org/10.1093/jnci/djad169

Brierley JD GM, Wittekind C (editors). TNM classification of malignant tumours. 8th ed ed. Chichester (UK): Wiley-Blackwell. 2017. DOI: https://doi.org/10.1002/9780471420194.tnmc26.pub3

Wendt M, Hammarstedt-Nordenvall L, Zupancic M, Friesland S, Landin D, Munck-Wikland E, et al. Long-Term Survival and Recurrence in Oropharyngeal Squamous Cell Carcinoma in Relation to Subsites, HPV, and p16-Status. Cancers. 2021;13(11):2553. DOI: https://doi.org/10.3390/cancers13112553

Nøst TH, Alcala K, Urbarova I, Byrne KS, Guida F, Sandanger TM, et al. Systemic inflammation markers and cancer incidence in the UK Biobank. Europ J Epidemiol. 2021;36(8):841-8. DOI: https://doi.org/10.1007/s10654-021-00752-6

Crusz SM, Balkwill FR. Inflammation and cancer: advances and new agents. Nature Rev Clin Oncol. 2015;12(10):584-96. DOI: https://doi.org/10.1038/nrclinonc.2015.105

Wu CY, Hu HY, Huang N, Chou YC, Li CP, Chou YJ. Albumin levels and cause-specific mortality in community-dwelling older adults. Preventive Med. 2018;112:145-51. DOI: https://doi.org/10.1016/j.ypmed.2018.04.015

Tang Q, Li X, Sun CR. Predictive value of serum albumin levels on cancer survival: a prospective cohort study. Front Oncol. 2024;14:1323192. DOI: https://doi.org/10.3389/fonc.2024.1323192

Luan CW, Yang HY, Tsai YT, Hsieh MC, Chou HH, Chen KS. Prognostic Value of C-Reactive Protein-to-Albumin Ratio in Head and Neck Cancer: A Meta-Analysis. Diagnostics (Basel, Switzerland). 2021;11(3):403. DOI: https://doi.org/10.3390/diagnostics11030403

Ferrandino RM, Roof S, Garneau J, Haidar Y, Bates SE, Park YA, et al. Neutrophil-to-lymphocyte ratio as a prognostic indicator for overall and cancer-specific survival in squamous cell carcinoma of the head and neck. Head Neck. 2020;42(10):2830-40. DOI: https://doi.org/10.1002/hed.26329

Varim C, Celik FD, Sunu C, Öztop KE, Aydın A, Yaylaci S, et al. The role of neutrophil albumin ratio in predicting the stage of non-small cell lung cancer. Europ Rev Med Pharmacological Sci. 2022;26(8):2900-5.

Ferro M, Babă DF, de Cobelli O, Musi G, Lucarelli G, Terracciano D, et al. Neutrophil percentage-to-albumin ratio predicts mortality in bladder cancer patients treated with neoadjuvant chemotherapy followed by radical cystectomy. Future Sci. 2021;7(7):Fso709. DOI: https://doi.org/10.2144/fsoa-2021-0008

Tingle SJ, Severs GR, Goodfellow M, Moir JA, White SA. NARCA: A novel prognostic scoring system using neutrophil-albumin ratio and Ca19-9 to predict overall survival in palliative pancreatic cancer. J Surg Oncol. 2018;118(4):680-6. DOI: https://doi.org/10.1002/jso.25209

Ko CA, Fang KH, Tsai MS, Lee YC, Lai CH, Hsu CM, et al. Prognostic Value of Neutrophil Percentage-to-Albumin Ratio in Patients with Oral Cavity Cancer. Cancers. 2022;14(19):4892. DOI: https://doi.org/10.3390/cancers14194892

Haddad CR, Guo L, Clarke S, Guminski A, Back M, Eade T. Neutrophil-to-lymphocyte ratio in head and neck cancer. J Med Imag Radiat Oncol. 2015;59(4):514-9. DOI: https://doi.org/10.1111/1754-9485.12305

Li X, Wu M, Chen M, Liu R, Tao Q, Hu Y, et al. The Association Between Neutrophil-Percentage-to-Albumin Ratio (NPAR) and Mortality Among Individuals With Cancer: Insights From National Health and Nutrition Examination Survey. Cancer Med. 2025;14(2):e70527. DOI: https://doi.org/10.1002/cam4.70527

Xie H, Jia P, Wei L, Ruan G, Zhang H, Ge Y, et al. Evaluation and validation of neutrophil to albumin ratio as a promising prognostic marker for all-cause mortality in patients with cancer: a multicenter cohort study. Nutrition (Burbank, Los Angeles County, Calif). 2024;121:112365. DOI: https://doi.org/10.1016/j.nut.2024.112365

Tawfik B, Mokdad AA, Patel PM, Li HC, Huerta S. The neutrophil to albumin ratio as a predictor of pathological complete response in rectal cancer patients following neoadjuvant chemoradiation. Anti-cancer Drugs. 2016;27(9):879-83. DOI: https://doi.org/10.1097/CAD.0000000000000411

Hu Z, Wang J, Xue Y, Zhang Q, Xu Q, Ji K, et al. The Neutrophil-to-Albumin Ratio as a New Predictor of All-Cause Mortality in Patients with Heart Failure. J Inflammat Res. 2022;15:701-13. DOI: https://doi.org/10.2147/JIR.S349996

Gong Y, Li D, Cheng B, Ying B, Wang B. Increased neutrophil percentage-to-albumin ratio is associated with all-cause mortality in patients with severe sepsis or septic shock. Epidemiol Infect. 2020;148:e87. DOI: https://doi.org/10.1017/S0950268820000771

Lan CC, Su WL, Yang MC, Chen SY, Wu YK. Predictive role of neutrophil-percentage-to-albumin, neutrophil-to-lymphocyte and eosinophil-to-lymphocyte ratios for mortality in patients with COPD: Evidence from NHANES 2011-2018. Respirology (Carlton, Vic). 2023;28(12):1136-46. DOI: https://doi.org/10.1111/resp.14589

Galdiero MR, Varricchi G, Loffredo S, Mantovani A, Marone G. Roles of neutrophils in cancer growth and progression. J Leukocyte Biol. 2018;103(3):457-64. DOI: https://doi.org/10.1002/JLB.3MR0717-292R

Jensen HK, Donskov F, Marcussen N, Nordsmark M, Lundbeck F, von der Maase H. Presence of intratumoral neutrophils is an independent prognostic factor in localized renal cell carcinoma. J Clin Oncol. 2009;27(28):4709-17. DOI: https://doi.org/10.1200/JCO.2008.18.9498

Gupta D, Lis CG. Pretreatment serum albumin as a predictor of cancer survival: a systematic review of the epidemiological literature. Nutrition J. 2010;9:69. DOI: https://doi.org/10.1186/1475-2891-9-69

Yoshikawa N, Yoshihara M, Tamauchi S, Ikeda Y, Yokoi A, Kajiyama H. Hypoalbuminemia for the prediction of survival in patients with stage IVB cervical cancer. PloS one. 2022;17(9):e0273876. DOI: https://doi.org/10.1371/journal.pone.0273876

Vasson MP, Talvas J, Perche O, Dillies AF, Bachmann P, Pezet D, et al. Immunonutrition improves functional capacities in head and neck and esophageal cancer patients undergoing radiochemotherapy: a randomized clinical trial. Clinical nutrition (Edinburgh, Scotland). 2014;33(2):204-10. DOI: https://doi.org/10.1016/j.clnu.2013.06.008

Gregory AD, Houghton AM. Tumor-associated neutrophils: new targets for cancer therapy. Cancer Res. 2011;71(7):2411-6. DOI: https://doi.org/10.1158/0008-5472.CAN-10-2583